Literature DB >> 16504803

Epidemiology of myomas.

Mark Payson1, Phyllis Leppert, James Segars.   

Abstract

Fibroids are a prevalent disorder occurring in at least half of American reproductive-age women. In general, the incidence and size increases with age. Most women never attribute or report any symptoms from their fibroids, and because of this the actual contribution of disease to symptoms of pelvic pain,menstrual symptoms, and infertility is poorly understood. The presence of fibroids can lead to multiple and disabling difficulties. Fibroids may cause pain and menstrual bleeding to the point of anemia. Fibroids clearly reduce fertility,increase preterm labor and delivery, and markedly increase the risk for cesarean delivery. Because the incidence varies according to population of interest, fibroids may explain some health disparities in different populations. For example,African Americans have a relatively poor outcome with assisted reproductive techniques compared with whites. Controlling for fibroid disease may explain this disparity, at least in part. Fibroids represent a tremendous public health burden on women and economic cost on society. Strategies to prevent, limit growth, and treat nonsurgically are needed. Fundamental and significant questions remain about fibroid disease,such as whether different clinical disease phenotypes (multiple versus single leiomyomas) contribute equally to symptoms and possess an equal likelihood of disease progression. For epidemiologic assessment of disease, a scoring system is urgently needed. Well-designed, controlled, prospective studies are still needed to define the natural history and correlate the presence of disease with symptomatology in women.

Entities:  

Mesh:

Year:  2006        PMID: 16504803      PMCID: PMC4152898          DOI: 10.1016/j.ogc.2005.12.004

Source DB:  PubMed          Journal:  Obstet Gynecol Clin North Am        ISSN: 0889-8545            Impact factor:   2.844


  31 in total

Review 1.  Uterine fibroids: the elephant in the room.

Authors:  Cheryl Lyn Walker; Elizabeth A Stewart
Journal:  Science       Date:  2005-06-10       Impact factor: 47.728

2.  Inherited susceptibility to uterine leiomyomas and renal cell cancer.

Authors:  V Launonen; O Vierimaa; M Kiuru; J Isola; S Roth; E Pukkala; P Sistonen; R Herva; L A Aaltonen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

3.  Predictors of leiomyoma recurrence after myomectomy.

Authors:  Magdi Hanafi
Journal:  Obstet Gynecol       Date:  2005-04       Impact factor: 7.661

4.  Age-specific incidence rates for self-reported uterine leiomyomata in the Black Women's Health Study.

Authors:  Lauren A Wise; Julie R Palmer; Elizabeth A Stewart; Lynn Rosenberg
Journal:  Obstet Gynecol       Date:  2005-03       Impact factor: 7.661

5.  A prospective study of hypertension and risk of uterine leiomyomata.

Authors:  Renée Boynton-Jarrett; Janet Rich-Edwards; Susan Malspeis; Stacey A Missmer; Rosalind Wright
Journal:  Am J Epidemiol       Date:  2005-04-01       Impact factor: 4.897

6.  Diet and uterine myomas.

Authors:  F Chiaffarino; F Parazzini; C La Vecchia; L Chatenoud; E Di Cintio; S Marsico
Journal:  Obstet Gynecol       Date:  1999-09       Impact factor: 7.661

7.  Variation in the incidence of uterine leiomyoma among premenopausal women by age and race.

Authors:  L M Marshall; D Spiegelman; R L Barbieri; M B Goldman; J E Manson; G A Colditz; W C Willett; D J Hunter
Journal:  Obstet Gynecol       Date:  1997-12       Impact factor: 7.661

8.  New concepts in the treatment of uterine leiomyomas.

Authors:  E A Stewart; R A Nowak
Journal:  Obstet Gynecol       Date:  1998-10       Impact factor: 7.661

9.  Familial leiomyomatosis cutis et uteri (Reed's syndrome).

Authors:  M P García Muret; R M Pujol; A Alomar; J Calaf; J M de Moragas
Journal:  Arch Dermatol Res       Date:  1988       Impact factor: 3.017

10.  A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata.

Authors:  L M Marshall; D Spiegelman; M B Goldman; J E Manson; G A Colditz; R L Barbieri; M J Stampfer; D J Hunter
Journal:  Fertil Steril       Date:  1998-09       Impact factor: 7.329

View more
  31 in total

1.  The impact of race as a risk factor for symptom severity and age at diagnosis of uterine leiomyomata among affected sisters.

Authors:  Karen L Huyck; Carolien I M Panhuysen; Karen T Cuenco; Jingmei Zhang; Hilary Goldhammer; Emlyn S Jones; Priya Somasundaram; Allison M Lynch; Bernard L Harlow; Hang Lee; Elizabeth A Stewart; Cynthia C Morton
Journal:  Am J Obstet Gynecol       Date:  2008-02       Impact factor: 8.661

2.  Activating transcription factor 3 gene expression suggests that tissue stress plays a role in leiomyoma development.

Authors:  Mark Payson; Minnie Malik; Sarah Siti-Nur Morris; James H Segars; Rebecca Chason; William H Catherino
Journal:  Fertil Steril       Date:  2008-08-09       Impact factor: 7.329

3.  Prevalence of uterine leiomyomas in lymphangioleiomyomatosis.

Authors:  Angelo M Taveira-Dasilva; Antoinette Rabel; Bernadette R Gochuico; Nilo A Avila; Joel Moss
Journal:  Fertil Steril       Date:  2011-09       Impact factor: 7.329

Review 4.  The impact of uterine leiomyomas on reproductive outcomes.

Authors:  H Cook; M Ezzati; J H Segars; K McCarthy
Journal:  Minerva Ginecol       Date:  2010-06

5.  1,25-dihydroxyvitamin D3 regulates expression of sex steroid receptors in human uterine fibroid cells.

Authors:  Ayman Al-Hendy; Michael P Diamond; Ahmed El-Sohemy; Sunil K Halder
Journal:  J Clin Endocrinol Metab       Date:  2015-01-27       Impact factor: 5.958

6.  Racial differences in fibroid prevalence and ultrasound findings in asymptomatic young women (18-30 years old): a pilot study.

Authors:  Erica E Marsh; Geraldine E Ekpo; Eden R Cardozo; Maureen Brocks; Tanaka Dune; Leeber S Cohen
Journal:  Fertil Steril       Date:  2013-03-15       Impact factor: 7.329

Review 7.  Biomarkers in uterine leiomyoma.

Authors:  Gary Levy; Micah J Hill; Torie C Plowden; William H Catherino; Alicia Y Armstrong
Journal:  Fertil Steril       Date:  2012-11-29       Impact factor: 7.329

8.  Nanomedicine for uterine leiomyoma therapy.

Authors:  Hazem Ali; Gokhan Kilic; Kathleen Vincent; Massoud Motamedi; Erik Rytting
Journal:  Ther Deliv       Date:  2013-02

9.  Leiomyoma cells in 3-dimensional cultures demonstrate an attenuated response to fasudil, a rho-kinase inhibitor, when compared to 2-dimensional cultures.

Authors:  Minnie Malik; Joy Britten; James Segars; William H Catherino
Journal:  Reprod Sci       Date:  2014-08-01       Impact factor: 3.060

10.  Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas.

Authors:  Linda Yu; Katrin Saile; Carol D Swartz; Hong He; Xiaolin Zheng; Grace E Kissling; Xudong Di; Shantelle Lucas; Stanley J Robboy; Darlene Dixon
Journal:  Mol Med       Date:  2008 May-Jun       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.